Cabaletta Bio, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Cabaletta Bio, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($44.87M) | Nov 10, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($45.13M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($45.13M) | Aug 7, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($35.94M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($35.94M) | May 15, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($35.94M) | Nov 10, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($30.63M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($27.60M) | Aug 7, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($27.60M) | Nov 10, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($25.05M) | May 15, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($25.05M) | Nov 10, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($25.05M) | Aug 7, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($16.45M) | Nov 14, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($14.49M) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($14.49M) | Aug 8, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($15.85M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($15.85M) | May 15, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($15.85M) | Nov 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($11.43M) | Nov 9, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($12.91M) | Nov 9, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($46.59M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($45.91M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($37.14M) | May 15, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($33.05M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($30.28M) | Aug 7, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($28.03M) | May 15, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($18.67M) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($15.89M) | Aug 8, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($16.96M) | May 15, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($11.78M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($13.06M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($13.00M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($11.56M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($11.15M) | Aug 11, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($9.71M) | May 12, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($8.42M) | Nov 1, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($8.19M) | Aug 5, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($7.90M) | May 3, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($5.03M) | Nov 10, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($3.80M) | Aug 6, 2020 |